Department of Orbit and Oculoplasty, Sadguru Netra Chikitsalya and Postgraduate Institute of Ophthalmology, Jankikund, Chitrakoot, Madhya Pradesh, India.
Department of Pediatric Ophthalmology and Strabismus, Sadguru Netra Chikitsalya and Postgraduate Institute of Ophthalmology, Jankikund, Chitrakoot, Madhya Pradesh, India.
Indian J Ophthalmol. 2021 May;69(5):1155-1160. doi: 10.4103/ijo.IJO_2404_20.
To study topical timolol (0.5%) as a first-line treatment in ophthalmic pyogenic granuloma (PG) in terms of safety and efficacy.
This was a prospective, interventional, single-arm study conducted at a tertiary eye care hospital in central India. Only new cases of PG were counseled to get enrolled in the study. A total of 40 patients were analyzed in the study. Topical timolol eye drop (0.5%) was started in each patient twice daily for 4-6 weeks duration. The patients were divided into five categories according to the percentage reduction in the size of PG as follows: i) 80-100% reduction - excellent responders, ii) 60-80% - good, iii) 40-60% - satisfactory, iv) 20-40% - poor, and v) <20% - very poor/nonresponder. After 6 months of starting treatment final evaluation was done.
The mean age of the patients was 23.5 ± 13.3 years. Etiology of the disease included chalazion (n = 11, 27.5%), trauma (n = 2, 5%), surgery (n = 7, 17.5%), foreign body (n = 2, 5%), and idiopathic (n = 18, 45%). An excellent response was achieved in 31 (77.5%) patients. Twenty-seven (67.5%) patients had complete resolution of lesions within 6 weeks. Recurrence of the lesion was not noticed in any patients.
Timolol 0.5% in topical form is a good treatment option for ophthalmic PG in all age groups. The treatment has no adverse effects when given to suitable individuals for a limited period.
研究局部噻吗洛尔（0.5%）作为眼科化脓性肉芽肿（PG）的一线治疗方法，评估其安全性和疗效。
这是一项在印度中部一家三级眼科医院进行的前瞻性、干预性、单臂研究。仅对新确诊的 PG 患者进行入组咨询。本研究共分析了 40 例患者。每位患者均每日使用 0.5%噻吗洛尔滴眼液滴眼两次，治疗持续 4-6 周。根据 PG 大小缩小百分比将患者分为五类：i）80-100%缩小-优秀反应者，ii）60-80%缩小-良好，iii）40-60%缩小-满意，iv）20-40%缩小-差，v）<20%缩小-极差/无反应者。治疗开始后 6 个月进行最终评估。
患者的平均年龄为 23.5 ± 13.3 岁。疾病的病因包括霰粒肿（n = 11，27.5%）、外伤（n = 2，5%）、手术（n = 7，17.5%）、异物（n = 2，5%）和特发性（n = 18，45%）。31 例（77.5%）患者获得了优秀的反应。27 例（67.5%）患者在 6 周内完全消退病变。没有患者出现病变复发。
0.5%噻吗洛尔局部用药是各年龄段眼科 PG 的一种良好治疗选择。在适当的个体中使用有限的时间内，该治疗方法没有不良反应。
